{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:03:11Z","timestamp":1784264591669,"version":"3.55.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003100","name":"F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003100","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00e9gion Grant Est, CHRU Nancy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inflammatory bowel disease (IBD) displays an increased venous and arterial thrombotic risk despite the common occurrence of intestinal bleeding. While some of the mechanisms leading to these thrombotic complications have been studied, other specific changes in the hemostasis profile of IBD patients have been less explored. One such example relates to von Willebrand factor (VWF) whose plasma levels have been reported to be modulated in IBD. Von Willebrand factor is a plasma glycoprotein crucial for hemostatic functions via roles both in platelet function and coagulation. High plasma VWF is a known risk factor for venous thromboembolism. In addition to its canonical roles in hemostasis, VWF is known to be directly or indirectly involved in other vascular processes such as maintenance of endothelial barrier integrity or proliferation of vascular smooth muscle cells. The purpose of this review is to recapitulate and update the existing data about VWF biology in IBD and to highlight its role both in the existing procoagulant phenotype and in vascular alterations that may occur in IBD.<\/jats:p>","DOI":"10.1093\/ibd\/izae142","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T02:25:46Z","timestamp":1720059946000},"page":"2500-2508","source":"Crossref","is-referenced-by-count":8,"title":["Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-565X","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Lagrange","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, DCAC , Nancy ,","place":["France"]},{"name":"CHRU Nancy, IHU INFINY , Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Usman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, NGERE, IHU INFINY , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-9387","authenticated-orcid":false,"given":"Dj\u00e9sia","family":"Arnone","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, NGERE, IHU INFINY , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2938-1383","authenticated-orcid":false,"given":"Patrick","family":"Lacolley","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, DCAC , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-5022","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Regnault","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, DCAC , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, NGERE, IHU INFINY , Nancy ,","place":["France"]},{"name":"Department of Gastroenterology, CHRU Nancy , Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]},{"name":"Groupe Hospitalier priv\u00e9 Ambroise Par\u00e9 - Hartmann, Paris IBD center , Neuilly sur Seine ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5152-9156","authenticated-orcid":false,"given":"C\u00e9cile V","family":"Denis","sequence":"additional","affiliation":[{"name":"HITh, UMR_S1176, INSERM, Universit\u00e9 Paris-Saclay , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"issue":"4","key":"2024121018560772800_CIT0001","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/ajg.2011.53","article-title":"Venous thromboembolism in inflammatory bowel disease: an epidemiological review","volume":"106","author":"Murthy","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"2024121018560772800_CIT0002","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology."},{"issue":"6","key":"2024121018560772800_CIT0003","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","article-title":"Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies","volume":"8","author":"Fumery","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2024121018560772800_CIT0004","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut."},{"key":"2024121018560772800_CIT0005","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cgh.2019.12.043","article-title":"Shedding light on hemostasis in patients with inflammatory bowel diseases","volume":"19","author":"Lagrange","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"12","key":"2024121018560772800_CIT0006","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/jth.12008","article-title":"von Willebrand factor: the old, the new and the unknown","volume":"10","author":"Lenting","year":"2012","journal-title":"J Thromb Haemost."},{"issue":"11","key":"2024121018560772800_CIT0007","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1161\/ATVBAHA.122.318179","article-title":"Regulation of VWF (Von Willebrand Factor) in inflammatory thrombosis","volume":"42","author":"Manz","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2024121018560772800_CIT0008","doi-asserted-by":"publisher","first-page":"blood.2023021915","DOI":"10.1182\/blood.2023021915","article-title":"Novel functions for Von Willebrand factor","author":"Atiq","year":"2024","journal-title":"Blood."},{"issue":"1","key":"2024121018560772800_CIT0009","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5482\/HAMO-16-06-0018","article-title":"Von Willebrand factor processing","volume":"37","author":"Brehm","year":"2017","journal-title":"Hamostaseologie."},{"issue":"15","key":"2024121018560772800_CIT0010","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2015-04-512731","article-title":"von Willebrand factor propeptide: biology and clinical utility","volume":"126","author":"Haberichter","year":"2015","journal-title":"Blood."},{"issue":"12","key":"2024121018560772800_CIT0011","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"9715","key":"2024121018560772800_CIT0012","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet."},{"issue":"7","key":"2024121018560772800_CIT0013","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation","volume":"15","author":"Kawecki","year":"2017","journal-title":"J Thromb Haemost."},{"issue":"4","key":"2024121018560772800_CIT0014","first-page":"273","article-title":"von Willebrand factor in the plasma of patients with rheumatic diseases","volume":"27","author":"Du\u0163u","year":"1989","journal-title":"Med Interne."},{"issue":"2","key":"2024121018560772800_CIT0015","first-page":"1979","article-title":"Roles of claudin-5 and von Willebrand factor in patients with rheumatoid arthritis","volume":"8","author":"Gurol","year":"2015","journal-title":"Int J Clin Exp Pathol."},{"issue":"3","key":"2024121018560772800_CIT0016","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/ar295","article-title":"Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)","volume":"3","author":"Scheja","year":"2001","journal-title":"Arthritis Res."},{"issue":"1","key":"2024121018560772800_CIT0017","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0026-0495(79)90169-0","article-title":"Increased von Willebrand factor in diabetes mellitus","volume":"28","author":"Lufkin","year":"1979","journal-title":"Metabolism."},{"issue":"24","key":"2024121018560772800_CIT0018","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1161\/CIRCULATIONAHA.108.792986","article-title":"Von Willebrand factor, type 2 diabetes and risk of cardiovascular disease: the Framingham offspring study","volume":"118","author":"Frankel","year":"2008","journal-title":"Circulation."},{"issue":"1","key":"2024121018560772800_CIT0019","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/15321819.2021.1941097","article-title":"Study of serum level and immunohistochemical expression of von Willebrand factor in psoriasis","volume":"43","author":"Bazid","year":"2022","journal-title":"J Immunoassay Immunochem."},{"issue":"5","key":"2024121018560772800_CIT0020","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.kint.2020.12.011","article-title":"A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure","volume":"99","author":"Tran","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"2024121018560772800_CIT0021","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00431-019-03513-6","article-title":"Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease","volume":"179","author":"Jakob","year":"2020","journal-title":"Eur J Pediatr."},{"issue":"3","key":"2024121018560772800_CIT0022","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3892\/etm.2011.432","article-title":"Von Willebrand factor, ADAMTS13 activity, TNF-\u03b1 and their relationships in patients with chronic kidney disease","volume":"3","author":"Shen","year":"2012","journal-title":"Exp Ther Med."},{"issue":"3","key":"2024121018560772800_CIT0023","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/jth.14686","article-title":"Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis","volume":"18","author":"Peetermans","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"2","key":"2024121018560772800_CIT0024","doi-asserted-by":"publisher","first-page":"e0247017","DOI":"10.1371\/journal.pone.0247017","article-title":"Characterization of ADAMTS13 and von Willebrand factor levels in septic and nonseptic ICU patients","volume":"16","author":"Singh","year":"2021","journal-title":"PLoS One."},{"issue":"6","key":"2024121018560772800_CIT0025","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"issue":"5","key":"2024121018560772800_CIT0026","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.7861\/clinmed.2020-0346","article-title":"Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19","volume":"20","author":"Ladikou","year":"2020","journal-title":"Clin Med (Lond)."},{"issue":"1","key":"2024121018560772800_CIT0027","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01183-9","article-title":"SARS-CoV-2 Spike protein promotes VWF secretion and thrombosis via endothelial cytoskeleton-associated protein 4 (CKAP4)","volume":"7","author":"Li","year":"2022","journal-title":"Sig Transduct Target Ther."},{"issue":"9","key":"2024121018560772800_CIT0028","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1182\/blood-2018-02-791533","article-title":"The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis","volume":"132","author":"Masias","year":"2018","journal-title":"Blood."},{"issue":"3","key":"2024121018560772800_CIT0029","doi-asserted-by":"publisher","first-page":"1801805","DOI":"10.1183\/13993003.01805-2018","article-title":"The ADAMTS13\u2013VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension","volume":"53","author":"Newnham","year":"2019","journal-title":"Eur Respir J."},{"issue":"Suppl 1","key":"2024121018560772800_CIT0030","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ijlh.13415","article-title":"ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy","volume":"43","author":"Henry","year":"2021","journal-title":"Int J Lab Hematol."},{"issue":"4","key":"2024121018560772800_CIT0031","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1177\/0192623313518664","article-title":"Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and\/or injury","volume":"42","author":"Brott","year":"2014","journal-title":"Toxicol Pathol."},{"issue":"14","key":"2024121018560772800_CIT0032","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1182\/blood-2013-08-508093","article-title":"Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome","volume":"123","author":"Hyseni","year":"2014","journal-title":"Blood."},{"issue":"3","key":"2024121018560772800_CIT0033","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10456-020-09762-6","article-title":"Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality","volume":"24","author":"Philippe","year":"2021","journal-title":"Angiogenesis."},{"issue":"3","key":"2024121018560772800_CIT0034","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10456-021-09789-3","article-title":"Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF\/ADAMTS13 ratio imbalance","volume":"24","author":"Philippe","year":"2021","journal-title":"Angiogenesis."},{"issue":"3","key":"2024121018560772800_CIT0035","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/00365529950173708","article-title":"Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation","volume":"34","author":"Meucci","year":"1999","journal-title":"Scand J Gastroenterol."},{"issue":"48","key":"2024121018560772800_CIT0036","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.3748\/wjg.v11.i48.7639","article-title":"Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation","volume":"11","author":"Zezos","year":"2005","journal-title":"World J Gastroenterol."},{"issue":"4","key":"2024121018560772800_CIT0037","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2174\/1570161111311040008","article-title":"Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target","volume":"11","author":"Lenting","year":"2013","journal-title":"Curr Vasc Pharmacol."},{"issue":"8","key":"2024121018560772800_CIT0038","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/s0002-9343(02)01345-1","article-title":"Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)","volume":"113","author":"Tsai","year":"2002","journal-title":"Am J Med."},{"issue":"1","key":"2024121018560772800_CIT0039","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2020003135","article-title":"Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism","volume":"5","author":"Edvardsen","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"2024121018560772800_CIT0040","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/ecco-jcc\/jjad198","article-title":"The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease","volume":"18","author":"Schellenberg","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2024121018560772800_CIT0041","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood-2005-03-1153","article-title":"A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B","volume":"106","author":"Hulstein","year":"2005","journal-title":"Blood."},{"issue":"3","key":"2024121018560772800_CIT0042","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MOH.0b013e3280dce531","article-title":"The presence of active von Willebrand factor under various pathological conditions","volume":"14","author":"Groot","year":"2007","journal-title":"Curr Opin Hematol."},{"issue":"2-3","key":"2024121018560772800_CIT0043","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000214859","article-title":"ADAMTS13 in health and disease","volume":"121","author":"Feys","year":"2009","journal-title":"Acta Haematol."},{"issue":"6","key":"2024121018560772800_CIT0044","doi-asserted-by":"publisher","first-page":"R273","DOI":"10.1186\/cc13115","article-title":"The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation","volume":"17","author":"Peigne","year":"2013","journal-title":"Crit Care."},{"issue":"26","key":"2024121018560772800_CIT0045","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.3748\/wjg.v23.i26.4796","article-title":"Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases","volume":"23","author":"Cibor","year":"2017","journal-title":"World J Gastroenterol."},{"issue":"Suppl 5","key":"2024121018560772800_CIT0046","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/hae.12984","article-title":"State of the art: von Willebrand disease","volume":"22","author":"James","year":"2016","journal-title":"Haemophilia."},{"issue":"4","key":"2024121018560772800_CIT0047","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/0016-5085(95)90197-3","article-title":"Inherited disorders of coagulation appear to protect against inflammatory bowel disease","volume":"108","author":"Thompson","year":"1995","journal-title":"Gastroenterology."},{"issue":"2","key":"2024121018560772800_CIT0048","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000116773","article-title":"Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects","volume":"26","author":"Papa","year":"2008","journal-title":"Dig Dis."},{"issue":"3","key":"2024121018560772800_CIT0049","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1111\/hae.13209","article-title":"Acquired von Willebrand syndrome in inflammatory bowel disease","volume":"23","author":"Di Sabatino","year":"2017","journal-title":"Haemophilia."},{"issue":"3","key":"2024121018560772800_CIT0050","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ajh.10120","article-title":"Turner syndrome associated with acquired von Willebrand disease, primary biliary cirrhosis, and inflammatory bowel disease","volume":"70","author":"Sokol","year":"2002","journal-title":"Am J Hematol."},{"issue":"4","key":"2024121018560772800_CIT0051","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ajh.10298","article-title":"Acquired von Willebrand\u2019s syndrome: a single institution experience","volume":"72","author":"Kumar","year":"2003","journal-title":"Am J Hematol."},{"issue":"2","key":"2024121018560772800_CIT0052","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1055\/s-00035024","article-title":"Acquired von Willebrand syndrome: data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb Haemost."},{"key":"2024121018560772800_CIT0053","doi-asserted-by":"publisher","first-page":"Unit-15.25","DOI":"10.1002\/0471142735.im1525s104","article-title":"Dextran sulfate sodium (DSS)-induced colitis in mice","volume":"104","author":"Chassaing","year":"2014","journal-title":"Curr Protoc Immunol."},{"issue":"1","key":"2024121018560772800_CIT0054","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1055\/s-0037-1603927","article-title":"ADAMTS13 deficiency worsens colitis and exogenous ADAMTS13 administration decreases colitis severity in mice","volume":"1","author":"Zitomersky","year":"2017","journal-title":"TH Open."},{"issue":"12","key":"2024121018560772800_CIT0055","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1016\/j.ajpath.2014.08.015","article-title":"The neurotensin-HIF-1\u03b1-VEGF\u03b1 axis orchestrates hypoxia, colonic inflammation, and intestinal angiogenesis","volume":"184","author":"Bakirtzi","year":"2014","journal-title":"Am J Pathol."},{"issue":"3","key":"2024121018560772800_CIT0056","doi-asserted-by":"publisher","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","article-title":"Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis","volume":"27","author":"Rokkas","year":"2018","journal-title":"J Gastrointestin Liver Dis."},{"issue":"10","key":"2024121018560772800_CIT0057","doi-asserted-by":"publisher","first-page":"e1000639","DOI":"10.1371\/journal.ppat.1000639","article-title":"Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans","volume":"5","author":"Urban","year":"2009","journal-title":"PLoS Pathog."},{"issue":"32","key":"2024121018560772800_CIT0058","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1093\/eurheartj\/ehz524","article-title":"S100A8\/A9 as a therapeutic target in myocardial infarction: cellular mechanisms, molecular interactions, and translational challenges","volume":"40","author":"Frangogiannis","year":"2019","journal-title":"Eur Heart J."},{"issue":"1","key":"2024121018560772800_CIT0059","doi-asserted-by":"publisher","first-page":"15660","DOI":"10.1038\/s41598-019-52184-8","article-title":"High plasma level of S100A8\/S100A9 and S100A12 at admission indicates a higher risk of death in septic shock patients","volume":"9","author":"Dubois","year":"2019","journal-title":"Sci Rep."},{"issue":"11","key":"2024121018560772800_CIT0060","doi-asserted-by":"publisher","first-page":"e91356","DOI":"10.1172\/jci.insight.91356","article-title":"Myeloid-related protein-14 regulates deep vein thrombosis","volume":"2","author":"Wang","year":"2017","journal-title":"JCI Insight."},{"issue":"2","key":"2024121018560772800_CIT0061","doi-asserted-by":"publisher","first-page":"e0115828","DOI":"10.1371\/journal.pone.0115828","article-title":"S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One."},{"issue":"3","key":"2024121018560772800_CIT0062","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.thromres.2013.11.007","article-title":"Role of multiligand\/RAGE axis in platelet activation","volume":"133","author":"Fuentes","year":"2014","journal-title":"Thromb Res."},{"issue":"23","key":"2024121018560772800_CIT0063","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1182\/blood-2011-02-338582","article-title":"Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms","volume":"117","author":"Ghosh","year":"2011","journal-title":"Blood."},{"key":"2024121018560772800_CIT0064","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3389\/fimmu.2019.01687","article-title":"Platelets in sepsis: an update on experimental models and clinical data","volume":"10","author":"Assinger","year":"2019","journal-title":"Front Immunol."},{"issue":"24","key":"2024121018560772800_CIT0065","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1182\/blood.2021014966","article-title":"S100A8\/A9 drives the formation of procoagulant platelets through GPIb\u03b1","volume":"140","author":"Colicchia","year":"2022","journal-title":"Blood."},{"key":"2024121018560772800_CIT0066","doi-asserted-by":"publisher","first-page":"643973","DOI":"10.3389\/fmed.2021.643973","article-title":"Intestinal mucosal wound healing and barrier integrity in IBD\u2013crosstalk and trafficking of cellular players","volume":"8","author":"Sommer","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"24","key":"2024121018560772800_CIT0067","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1182\/blood.2019000510","article-title":"The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing","volume":"133","author":"Ishihara","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2024121018560772800_CIT0068","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2018-01-769018","article-title":"von Willebrand factor regulation of blood vessel formation","volume":"132","author":"Randi","year":"2018","journal-title":"Blood."},{"key":"2024121018560772800_CIT0069","doi-asserted-by":"publisher","first-page":"1143293","DOI":"10.3389\/fcvm.2023.1143293","article-title":"Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue","volume":"10","author":"Gabbiadini","year":"2023","journal-title":"Front Cardiovasc Med."},{"key":"2024121018560772800_CIT0070","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CEG.S243478","article-title":"Cardiovascular risk in individuals with inflammatory bowel disease","volume":"13","author":"Biondi","year":"2020","journal-title":"Clin Exp Gastroenterol."},{"issue":"2","key":"2024121018560772800_CIT0071","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14309\/ajg.0000000000002502","article-title":"Atherosclerosis as a risk factor of inflammatory bowel disease: a population-based case-control study","volume":"119","author":"Faye","year":"2024","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2024121018560772800_CIT0072","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.v98.5.1424","article-title":"Localized reduction of atherosclerosis in von Willebrand factor\u2013deficient mice","volume":"98","author":"Methia","year":"2001","journal-title":"Blood."},{"issue":"2","key":"2024121018560772800_CIT0073","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/cvr\/cvab042","article-title":"The VWF\/LRP4\/\u03b1V\u03b23-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells","volume":"118","author":"Lagrange","year":"2022","journal-title":"Cardiovasc Res."},{"issue":"7","key":"2024121018560772800_CIT0074","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/MCG.0000000000000408","article-title":"Antitumor necrosis factor-\u03b1 therapy is associated with reduced risk of thromboembolic events in hospitalized patients with inflammatory bowel disease","volume":"50","author":"deFonseka","year":"2016","journal-title":"J Clin Gastroenterol."},{"issue":"12","key":"2024121018560772800_CIT0075","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ibd\/izaa351","article-title":"Anti-TNF-\u03b1 treatment reduces the baseline procoagulant imbalance of patients with inflammatory bowel diseases","volume":"27","author":"Tripodi","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024121018560772800_CIT0076","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cgh.2014.07.017","article-title":"Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease","volume":"13","author":"Higgins","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2024121018560772800_CIT0077","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/exd.14582","article-title":"Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris","volume":"31","author":"Koschitzky","year":"2022","journal-title":"Exp Dermatol."},{"issue":"5","key":"2024121018560772800_CIT0078","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"issue":"9","key":"2024121018560772800_CIT0079","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium","volume":"113","author":"Narula","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2024121018560772800_CIT0080","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejim.2019.06.006","article-title":"Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: a multicenter, observational study in primary inflammatory bowel disease centers","volume":"66","author":"Tursi","year":"2019","journal-title":"Eur J Intern Med."},{"issue":"7","key":"2024121018560772800_CIT0081","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"2024121018560772800_CIT0082","doi-asserted-by":"publisher","first-page":"1189389","DOI":"10.3389\/fphar.2023.1189389","article-title":"Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae142\/58429269\/izae142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/12\/2500\/60924217\/izae142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/12\/2500\/60924217\/izae142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:51:41Z","timestamp":1733860301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/12\/2500\/7705639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":82,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,3]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae142","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,3]]}}}